Carisma is pioneering the development of a novel type of cell therapy using the patient’s own immune cells to develop targeted therapies that attack cancer.
Our CAR-Macrophage cell therapies are designed to both directly attack cancer cells, whilst at the same time, trigger a broader response from the patient’s own immune system, recruiting T cells, NK cells, and dendritic cells to fight the cancer.
A clinical trial is a study used to learn more about a treatment for a disease or condition. People with the condition being studied are enrolled as volunteers. The purpose of a clinical trial is to determine the safety of a treatment and how well it works.
Clinical trials follow strict guidelines laid out by federal regulatory agencies, such as the U.S. Food and Drug Administration. For more information, visit the U.S. Food and Drug Administration’s website.
We are currently enrolling patients in a Phase 1 clinical trial of CT-0508 in various clinical sites in the U.S. CT-0508 is a cell therapy investigational product derived from the patient’s own immune cells. It is comprised of CAR-Macrophages designed to bind to and kill cancer cells that overexpress the HER2 receptor.
One of the primary objectives of the Phase 1 clinical trial is to assess its safety and tolerability in patients with advanced cancers who have already previously received other anticancer therapies. We are currently recruiting patients at:
Carisma Therapeutics is focused on developing innovative approaches that have the potential to create life-changing cellular therapies for patients with cancer and other serious disorders. Toward that end, we conduct clinical trials to assess the safety and effectiveness of investigational medicines and we encourage awareness of and participation in clinical trials.
In some cases, when it is not possible for a patient to participate in a clinical trial, the patient’s physician may seek access to a Carisma investigational medicine outside of the clinical trial setting. These situations are often referred to as managed access, expanded access, early access, preapproval access, compassionate use or emergency use.
When necessary, and at the appropriate stage of development, Carisma Therapeutics will consider providing an investigational drug outside of a clinical trial. This will take effect after clinical data is available, for patients who have the serious or life-threatening diseases for which Carisma Therapeutics is developing its investigational product(s), who have exhausted all available therapies and are unable to participate in clinical trials. At such time, Carisma intends to provide additional criteria for which expanded access requests would be evaluated. At our current early stage of drug development and clinical trials, Carisma does not have sufficient clinical data or sufficient evidence of clinical safety and efficacy of our investigational drugs to support expanded access.
We understand patients and families may have questions about immunotherapy and how it works.
We invite you to contact us to learn more. We will always do our best to answer your important questions in a timely manner.